The Leukemia & Lymphoma Society's Therapy Acceleration Program Non-Profit Profile - aVenture Research
The Leukemia & Lymphoma Society's Therapy Acceleration Program
Accelerating blood cancer therapeutics in NYC.
50
Operating
New York City, NY, US🇺🇸United States
The Leukemia & Lymphoma Society's Therapy Acceleration Program (TAP) is a strategic venture philanthropy initiative founded to accelerate the development of innovative blood cancer therapeutics. Based in New York City, TAP's core mission is to change the standard of care for blood cancer patients while generating a return on investment for the Leukemia & Lymphoma Society's broader mission. TAP focuses on funding and supporting the development of novel treatments that have the potential to significantly improve patient outcomes.
Notable affiliated people include former TAP partners like X4 Pharmaceuticals, which achieved FDA approval for Mavorixafor, a treatment for WHIM syndrome. TAP's key achievements include advancing multiple therapeutic candidates through critical stages of development, thereby impacting the lives of blood cancer patients. The program has made significant strides in the medical field by fostering innovation and expediting the availability of life-saving treatments.
